17:35 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

APTO-253: Development delayed

Aptose said it will “temporarily delay clinical activities” for its IV APTO-253 to allow the company to investigate the cause of manufacturing issues. Aptose said it will prioritize its resources on preclinical cancer candidate CG026806...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Company News

CrystalGenomics, Aptose Biosciences deal

CrystalGenomics granted Aptose an exclusive option to license rights to CG026806 outside of China and Korea. CrystalGenomics will receive an upfront payment of $1 million and is eligible for a $2 million option exercise payment...
02:43 , Jun 9, 2016 |  BC Extra  |  Company News

Aptose, CrystalGenomics in deal for multi-kinase inhibitor

CrystalGenomics Inc. (KOSDAQ:083790) granted Aptose Biosciences Inc. (TSX:APS; NASDAQ:APTO) an exclusive option to license rights to CG026806 outside of China and Korea. The compound is a small molecule inhibitor of Bruton's tyrosine kinase (Btk) ,...